Notebook

DISEASE RESEARCH SUPPORT In response to a perceived need for increased clinical research funding, the Doris Duke Charitable Foundation recently established the Doris Duke Distinguished Clinical Scientist Award Program. The Foundation will give $600,000 a year for five years to four research teams studying either cancer, AIDS, heart disease, or sickle cell anemia and related blood disorders. According to Alan Altschuler, the Foundation's acting program director for medical research, the clinic

| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

DISEASE RESEARCH SUPPORT In response to a perceived need for increased clinical research funding, the Doris Duke Charitable Foundation recently established the Doris Duke Distinguished Clinical Scientist Award Program. The Foundation will give $600,000 a year for five years to four research teams studying either cancer, AIDS, heart disease, or sickle cell anemia and related blood disorders. According to Alan Altschuler, the Foundation's acting program director for medical research, the clinical awards program is geared toward "bench to bedside" research involving scientists who are "seeking to convert scientific findings into real treatments for people." The grants are not meant to support specific research proposals, but rather to supplement the salaries and laboratory expenses of clinical researchers who are already receiving National Institutes of Health funding. They will only be offered to senior medical scientists at the 25 medical schools that receive the greatest amount of support from the NIH for ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies